ALDX Aldeyra Therapeutics, Inc.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
1.2
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Aldeyra Therapeutics Receives Nasdaq Non-Compliance Notice for Minimum Bid Price
Aldeyra Therapeutics, Inc. (ALDX) announced it received a notice from Nasdaq indicating that the company is not in compliance with the minimum bid price...
Aldeyra Therapeutics Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026
Analysts expect Aldeyra Therapeutics to report a Q3 2026 consensus net loss of $0.11 per share on estimated revenue of $1.25 million, with the stock currently...
Aldeyra Requests FDA Review Transfer for ADX-2191, Withdraws Special Protocol Assessment
Aldeyra Therapeutics announced a significant change in its regulatory strategy for ADX-2191, its drug candidate for primary vitreoretinal lymphoma (PVRL). The...
Aldeyra Therapeutics Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
For the third quarter of 2026, analysts expect Aldeyra Therapeutics to report a consensus revenue of $2.50 million and an EPS loss of -$0.11, with the stock...